Gyre Therapeutics (GYRE) Competitors

Cytokinetics (NASDAQ:CYTK) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.

Is CYTK or GYRE more profitable?

Gyre Therapeutics has a net margin of -84.57% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-17,906.25%	N/A	-50.21%
Gyre Therapeutics	-84.57%	-118.43%	-71.97%

Do analysts rate CYTK or GYRE?

Cytokinetics currently has a consensus price target of $74.44, suggesting a potential upside of 131.80%. Given Cytokinetics' higher probable upside, equities analysts clearly believe Cytokinetics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Gyre Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor CYTK or GYRE?

In the previous week, Cytokinetics had 22 more articles in the media than Gyre Therapeutics. MarketBeat recorded 24 mentions for Cytokinetics and 2 mentions for Gyre Therapeutics. Cytokinetics' average media sentiment score of 0.75 beat Gyre Therapeutics' score of 0.48 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	11 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gyre Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor CYTK or GYRE?

Cytokinetics received 828 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 79.94% of users gave Cytokinetics an outperform vote.

Company	Underperform	Outperform
Cytokinetics	Outperform Votes 829 79.94%	Underperform Votes 208 20.06%
Gyre Therapeutics	Outperform Votes 1 100.00%	Underperform Votes No Votes

Which has more volatility and risk, CYTK or GYRE?

Cytokinetics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.

Which has stronger earnings and valuation, CYTK or GYRE?

Gyre Therapeutics has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$19.22M	199.56	-$526.24M	-$5.29	-6.07
Gyre Therapeutics	$100.64M	10.45	-$92.93M	$0.02	560.75

Do insiders and institutionals hold more shares of CYTK or GYRE?

24.0% of Gyre Therapeutics shares are held by institutional investors. 2.7% of Cytokinetics shares are held by company insiders. Comparatively, 19.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Gyre Therapeutics beats Cytokinetics on 10 of the 19 factors compared between the two stocks.